A Multicenter Adaptive Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Brief description of study

COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There are no approved medicines to treat COVID-19. This research is to test an experimental medicine, remdesivir, in adult patients that are hospitalized with COVID-19. The drug has been tested before in humans with other diseases. This research is to see if it is safe and effective in treating patients with COVID-19. Participants will get either remdesivir or a placebo (aninactive medicine), along with the best standard of care for up to 10 days.

Clinical Study Identifier: s20-00286

ClinicalTrials.gov Identifier: NCT04280705

Principal Investigator: Mark J. Mulligan.

Other Investigators: Ellie R. Carmody, Henry J. Neumann, Tania Kupferman, Joseph O Rahimian, Vinh P Pham, Mary Christine Olson, Sarah E. Hochman, Kerry L. Dierberg, Anand Viswanathan, Benjamin J Eckhardt.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies